Bioventus (NASDAQ:BVS) Issues Quarterly Earnings Results

Bioventus (NASDAQ:BVS) posted its earnings results on Tuesday. The company reported $0.15 EPS for the quarter, Zacks reports. Bioventus had a positive return on equity of 23.04% and a negative net margin of 0.03%.

Bioventus Stock Up 0.2%

Shares of BVS stock opened at $6.56 on Tuesday. The company has a debt-to-equity ratio of 1.48, a quick ratio of 0.96 and a current ratio of 1.48. The business’s 50-day moving average price is $6.94. Bioventus has a 12-month low of $5.81 and a 12-month high of $14.38. The company has a market capitalization of $542.38 million, a price-to-earnings ratio of 13.10 and a beta of 0.80.

Analysts Set New Price Targets

Several equities research analysts have issued reports on BVS shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bioventus in a research note on Wednesday, October 8th. Wall Street Zen raised Bioventus from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 9th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Bioventus Company Profile

Bioventus Inc a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body’s natural healing process in the United States and internationally. The company’s portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products.